28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Early NPS burden as well as NPS severity progression rate, independently of cognitive status, might be useful clinical metrics and may help predict underlying pathological diagnoses. 3 key findings →
Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Patients with Mild Cognitive Impairment (MCI) are at high risk of progression to Alzheimer's dementia. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
KL -VSHET may help protect against amyloid pathology, particularly in the presence of APOE ε4, and regardless of APOE status in aMCI-AD. 5 key findings →
Participants: 223 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ApoE4 did not moderate the EF and falls relationship (p ≥ 0.05). 5 key findings →
Design: cross-sectional Participants: 486 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our findings suggest that restoration of the expression of nuclear-encoded OXPHOS genes in aging could be a viable strategy for blunting AD progression. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mild Cognitive Impairment (MCI) is a transitional stage between normal aging and dementia and people with MCI are at high risk of progression to dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Approximately half of the sample were persistently food secure, 17% became food secure, 14% became FI, and 15% experienced persistent FI. 5 key findings →
Participants: 9,654 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Aging is regarded as a major risk factor for neurodegenerative diseases. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Caregivers in the control conditions reported significantly worsening sleep efficiency whereas in comparison, those in the active conditions reported improving sleep efficiency. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy associated with repetitive head impact (RHI) exposure. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hyperphosphorylation of the microtubule-associated protein tau is hypothesized to lead to the development of neurofibrillary tangles in select brain regions during normal aging and in Alzheimer disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Social networks shrank linearly as death approached. 5 key findings →
Participants: 2,301 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
EOD participants reported the highest mean levels of all psychosocial outcomes (e.g., everyday discrimination score of 8.3 in EOD vs 4.6 in LOD and 6.8 in no-dementia). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's dis ease (AD) is a leading cause of mortality in the developed world with 70% risk attributable to genetics. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia disproportionately affects Hispanic/Latino caregivers, and while some interventions exist, their consideration of intersectional factors remains unclear. 1 key finding →
Participants: 41 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
-weighted magnetic resonance images of 41,708 cognitively normal adults in the UK Biobank. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Four main themes were identified: (1) reasons family caregivers may not choose formal care, (2) perceived benefits of formal care, (3) how family caregivers choose formal care, and (4) recommendations for delivering information about formal care options. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The smart device system to monitor tremors and to recognize its phenotypes for better outcomes of deep brain stimulation, applications evaluating fine motor functions, AI integrated electroencephalogram learning to diagnose epilepsy and psychological non-epileptic seizure, predict outcome of seizure surgeries, recognize patterns of autonomic instability to prevent sudden unexpected death in epilepsy (SUDEP), identify the pattern of complex algorithm in neuroimaging classifying cognitive impairment, differentiating and classifying concussion phenotypes, smartwatches monitoring atrial fibrillation to prevent strokes, and prediction of prognosis in dementia are unique examples of experimental utilizations of AI in the field of neurology. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
's < 0.05). The findings suggest that neighborhood-level social deprivation might influence memory and motor status, primarily through its impact on motor brain health. 1 key finding →
Participants: 22 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Although White and non-White participants were both willing to test (∼77%), non-White participants were approximately four times more likely to test only if their results were not shared with their medical provider/insurer. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of these, a growing number have secured funding, initiated collaborations, contributed to dementia palliative care research, and increased confidence and comfort with conducting clinical trials (p<.05). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Fifty-four participants (~8% response rate) from the MindCrowd web-based cohort (mean age of 62.39 years; 39 females; and 23 APOE ε4 carriers) completed 75 trials of Super G. Results show that Super G performance was significantly associated with each of the targeted risk factors. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →